XML 18 R9.htm IDEA: XBRL DOCUMENT v3.22.2
REVENUE
 6 Months Ended
Jun. 30, 2022
Revenue from Contract with Customer [Abstract]  
REVENUE REVENUE
Product Revenue
Disaggregation of the product revenue by type of customer for the three and six months ended June 30, 2022 and 2021, respectively:
Three Months Ended
June 30,		Six Months Ended
June 30,
2022202120222021
Public sector entities$3,823 $105,029 $5,433 $167,120 
Private sector customers80,528 32,394 256,372 34,802 
Total product revenue$84,351 $137,423 $261,805 $201,922 
Product revenue for the three and six months ended June 30, 2022 includes an immaterial amount of service revenue generated from telemedicine and proctoring services provided to customers. Revenue generated from proctoring is recognized over the term of the contracts with customers.                            
The following table sets forth the Company’s product gross profit and product gross profit (loss) margin for the three and six months ended June 30, 2022 and 2021:
Three Months Ended
June 30,		Six Months Ended
June 30,
2022202120222021
Product revenue$84,351$137,423$261,805$201,922
Cost of product revenue101,89855,142188,59585,177
Product gross profit (loss)$(17,547)$82,281$73,210$116,745
Product gross profit (loss) margin(21)%60 %28 %58 %

During the three and six months ended June 30, 2022, the Company recorded a charge of $42.8 million (the “inventory charge”) primarily related to excess and obsolescent inventory that is reflected within the cost of product revenue line item of the condensed statements of operations. This charge is primarily related to an overbuild of inventory and, in addition, identification of certain products which are not expected to perform in line with the Company’s quality
standards. Of the $42.8 million charge, $30.6 million was recorded to inventory reserve and $12.3 million was recorded to product warranty reserve.

DoD Agreement
In October 2020, the Company entered into a $480.9 million agreement with the U.S. government for the purchase of its Cue COVID-19 Test to meet the unprecedented demand for rapid and accurate molecular diagnostic testing (the “U.S. DoD Agreement”). The Company delivered all of the agreed upon products under the agreement prior to its expiration on December 31, 2021. The U.S. DoD Agreement provided for a $184.6 million upfront payment (the “U.S. DoD Advance”) to facilitate the scaling of the Company’s manufacturing capacity, which was received upon signing the contract. The U.S. DoD Agreement did not provide for the funds to be utilized in any specific manner beyond furthering the purposes of the agreement. The Company was not required to segregate, nor was the Company required to obtain the approval of the U.S. government to use the funds advanced to it under the agreement. The remaining $296.3 million of the agreement was due to the Company upon the delivery of Cue Readers, Cue COVID-19 Test Kits and Cue Control Swab Packs. The U.S. DoD Agreement also provided that, as soon as possible after the completion of the initial U.S. DoD Agreement, the Company and the U.S. government would negotiate in good faith to enter into a follow-on supply agreement based on federal acquisition regulations (a FAR-based contract). The U.S. DoD Agreement provides the U.S. DoD with the right to purchase no more than 45% of our quarterly production for the duration of the follow-on contract at a specified discount, subject to a price floor as part of this follow-on contract. The U.S. government is also entitled to certain administrative reporting but does not receive the right to any intellectual property or know-how. The agreement term ended upon completion of the Company’s performance obligations in December 2021.
Contract Assets and Liabilities
Contract assets primarily relate to the Company’s conditional right to consideration for performance obligations satisfied through direct-to-consumer sales but not billed at the reporting date. Net contract assets were $1.6 million and $1.1 million as of June 30, 2022 and December 31, 2021, respectively, and were recorded in other current assets on the balance sheets.
Contract liabilities primarily relate to the U.S. DoD Advance and payments received from customers in advance of performance under the contracts. Contract liabilities are recorded in current and non-current deferred revenue on the balance sheets. The activity related to contract liabilities for the six months ended June 30, 2022 is as follows:
Amount
Balance at December 31, 2021
$92,448 
Unearned revenue from cash received during the period, excluding amounts recognized as revenue during the period3,411 
Revenue recognized related to contract liability balance at the beginning of the period— 
Balance at June 30, 2022
$95,859 
Grant and Other Revenue
Grant and other revenue relate to a cost reimbursement agreement with the Biomedical Advanced Research and Development Authority (“BARDA”). The Company generated $3.3 million and $5.3 million of revenue related to the agreement with BARDA during the three and six months ended June 30, 2022, respectively. The Company generated $0 of revenue related to the agreement with BARDA during the three and six months ended June 30, 2021.

Accounts Receivable
The allowance for doubtful accounts represents the Company’s estimate of probable credit losses relating to accounts receivable and is determined based on historical experience and other specific account data. Amounts are written off against the allowances for doubtful accounts when the Company determines that a customer account is uncollectible. As of June 30, 2022 and December 31, 2021, the Company’s allowance for doubtful accounts was $0.8 million and $0.3 million, respectively.